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hosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
) is the
obligatory precursor of inositol 1,4,5-trisphosphate
(InsP
 
3
 
 or IP
 
3
 
) and is therefore critical to intracellular
Ca
 
2
 
 
 
 signaling. Using RNA interference (RNAi), we iden-
tiﬁed the short splice variant of type I phosphatidylinosi-
tol 4-phosphate 5-kinase 
 
 
 
 (PIP5KI
 
 
 
87) as the major
contributor of the PIP
 
2
 
 pool that supports G protein–cou-
pled receptor (GPCR)-mediated IP
 
3
 
 generation. PIP5KI
 
 
 
87
RNAi decreases the histamine-induced IP
 
3
 
 response and
P
 
Ca
 
2
 
 
 
 ﬂux by 70%. Strikingly, RNAi of other PIP5KI isoforms
has minimal effect, even though some of these isoforms
account for a larger percent of total PIP
 
2
 
 mass and have
previously been implicated in receptor mediated endo-
cytosis or focal adhesion formation. Therefore, PIP5KI
 
 
 
87’s
PIP
 
2
 
 pool that supports GPCR-mediated Ca
 
2
 
 
 
 signaling is
functionally compartmentalized from those generated by
the other PIP5KIs.
 
Introduction
 
Phosphatidylinositol 4,5-bisphosphate (PIP
 
2
 
) regulates multiple
plasma membrane (PM) functions (Doughman et al., 2003; Yin
and Janmey, 2003), and it is also a substrate for PLC-mediated
inositol 1,4,5-trisphosphate (InsP
 
3
 
 or IP
 
3
 
) generation. In spite of
PIP
 
2
 
’s obligatory role as an IP
 
3
 
 precursor, and the importance of
IP
 
3
 
 mediated Ca
 
2
 
 
 
 signaling, surprisingly little is known about
the identity of the phosphoinositide kinases involved. Unlike
yeast, which has a single type I phosphatidylinositol 4-phos-
phate 5-kinase (PIP5KI) that synthesizes PIP
 
2
 
 (Audhya and
Emr, 2003), mammals have three major PIP5KI isoforms named
 
 
 
, 
 
 
 
 and 
 
 
 
 (Doughman et al., 2003).
PIP5KI
 
 
 
 has two splice variants (PIP5KI
 
 
 
87 and 90) that
are distinguished by a 28–amino acid extension at the COOH
terminus of PIP5KI
 
 
 
90 (Di Paolo et al., 2002; Ling et al.,
2002; Fig. 1 A). PIP5KI
 
 
 
90 is particularly enriched in neurons
(Wenk et al., 2001); it is the major PIP
 
2
 
 synthesizing enzyme at
the synapse, where it has been implicated in the regulation of
clathrin coat recruitment, actin dynamics (Wenk et al., 2001)
and focal adhesion formation (Di Paolo et al., 2002; Ling et al.,
2002). In contrast, PIP5KI
 
 
 
87 is not involved in focal adhesion
formation or clathrin-mediated endocytosis (in HeLa cells;
Padron et al., 2003).
Here, we examined the role of PIP5KI
 
 
 
87 in intracellular
Ca
 
2
 
 
 
 signaling. Previous biochemical studies have shown that
cells have agonist-sensitive and -insensitive PIP
 
2
 
 pools (Koreh
and Monaco, 1986). Inhibitor studies suggest that the agonist-
sensitive pool can be further classified as constitutive or de
novo generated in response to agonists (Nakanishi et al., 1995).
Some of these pools are enriched in cholesterol–sphingolipid
raft domains (Pike and Casey, 1996) and the stringent spatial
and temporal regulation of Ca
 
2
 
 
 
 may be specified by as-
sembling key players into supramolecular signaling complexes
(Delmas et al., 2004). We now report that PIP5KI
 
 
 
87 is the
major source of the agonist-sensitive PM PIP
 
2
 
 pool that fuels
the initial Ca
 
2
 
 
 
 response to external stimuli.
 
Results and discussion
 
Knockdown of PIP5KI
 
 
 
87 by RNA 
interference
 
We use small interfering RNA (siRNA) mediated RNA inter-
ference (RNAi) to knockdown each PIP5KI individually (Padron
et al., 2003). Anti-PIP5KI
 
 
 
pan antibody recognizes a sharp 87-kD
band and a slower migrating diffuse band (Fig. 1 B) which is
probably hyperphosphorylated PIP5KI
 
 
 
87 (Park et al., 2001;
Wenk et al., 2001). Anti-PIP5KI
 
 
 
pan stains the PM, the perinu-
clear region and the nucleus (Fig. 1 D). Low level HA-PIP5KI
 
 
 
87
overexpression confirms that PIP5KI
 
 
 
 is enriched in the PM and
punctate internal structures, but rules out nuclear localization.
Biochemical fractionation shows that 60% of PIP5KI
 
 
 
87
is sedimented by high speed centrifugation (Fig. 1 E), and
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approximately two thirds of this is associated with the PM
enriched fraction. PIP5KI
 
 
 
 is much more membrane bound,
whereas PIP5KI
 
 
 
 is least membrane associated. Therefore,
these PIP5KIs have different patterns of membrane association.
Nevertheless, each can potentially generate PIP
 
2
 
 at the PM and
internal membranes.
Because it is not possible to knockdown PIP5KI
 
 
 
87 ex-
clusively, we compared the effects of siRNA directed against
both PIP5KI
 
 
 
 isoforms (PIP5KI
 
 
 
pan) to that of PIP5KI
 
 
 
90
alone. PIP5KI
 
 
 
pan siRNA decreases all PIP5KI
 
 
 
 bands in
Western blots (Fig. 1 B) and reduces PM and cytoplasmic anti-
PIP5KI
 
 
 
 immunofluorescence, but not the nonspecific nuclear
staining (Fig. 1 D). PIP5KI
 
 
 
90 siRNA has little effect on either
PIP5KI
 
 
 
 bands (Fig. 1 B), even though quantitative real-time
PCR established that PIP5KI
 
 
 
90 mRNA is decreased by
70% (Fig. 1 C). We conclude that HeLa cells have very little
PIP5KI
 
 
 
90.
Unexpectedly, PIP5KI
 
 
 
pan siRNA preferentially knocks
down PIP5K
 
 
 
87 mRNA relative to PIP5KI
 
 
 
90. Because
PIP5K
 
 
 
87 is more abundant than PIP5K
 
 
 
90 in HeLa cells and
PIP5K
 
 
 
pan siRNA generates a distinct phenotype (compared
with that of PIP5K
 
 
 
90 siRNA), the PIP5KI
 
 
 
pan siRNA ef-
fects described here can be attributed primarily to PIP5KI
 
 
 
87
knockdown. Importantly, PIP5KI
 
 
 
pan siRNA has almost no
effect on PIP5KI
 
 
 
 and 
 
 
 
 protein expression (Fig. 1 B), estab-
lishing that the PIP5KI
 
 
 
87 knockdown phenotype is not com-
plicated by compensatory changes in the other PIP5KIs. This
was originally a concern, because we have previously found
that knockdown of one PIP5KI induces changes in the mRNA
level of some other PIP5KIs (Padron et al., 2003).
 
PIP5KI
 
 
 
87 is the major supplier of the 
PIP
 
2
 
 pool that supports GPCR-mediated 
Ca
 
2
 
 
 
 signaling
 
Histamine binding to the H1 type G protein–coupled receptor
(GPCR) in HeLa cells (Tilly et al., 1990) initiates a PLC
 
 
 
 acti-
vation cascade that culminates in the hydrolysis of PIP
 
2
 
 to gen-
erate IP
 
3
 
 and diacylglycerol. When control cells were stimu-
lated with a supramaximal histamine dose (100 
 
 
 
M), they
generate a transient robust IP
 
3
 
 response (Fig. 2 A). PIP5KI
 
 
 
87
RNAi decreases the initial IP
 
3
 
 peak by 69% [to 10 
 
 
 
 3 pmol
IP
 
3
 
/mg protein (
 
n 
 
  
 
5)] (Fig. 2, A and B). Neither PIP5KI
 
 
 
90
nor PIP5KI
 
 
 
 RNAi has any apparent effect, and PIP5KI
 
 
RNAi only decreases the initial IP3 peak slightly [by 11%; to
28   2 pmol/mg protein (n   3)] (Fig. 2 B). Although we can-
not rule out a small contribution by PIP5KI  or   because each
is less completely knocked down than PIP5KI , we can con-
clude that PIP5KI 87 is the dominant regulator.
Consistent with a decrease in IP3 production,
PIP5KI pan RNAi also attenuates histamine-induced Ca
2  sig-
Figure 1. PIP5KI  RNAi. (A) PIP5KI  siRNA design. Pan siRNA is directed
against both isoforms. (B) PIP5KI  protein knockdown. Effect of PIP5K 
RNAi on protein expression of the targeted and nontargeted PIP5KIs.
Western blots were probed with isoform specific antibodies. Additional
data are provided in Table S1, available at http://www.jcb.org/cgi/
content/full/jcb.200408008/DC1. (C) Quantitative real-time PCR. PCR
primers were used to quantitate PIP5KI pan and PIP5KI 90 mRNA and
PIP5KI 87 mRNA was calculated from the difference. Numbers indicate
the amounts of each isoform relative to PIP5KI 90 in control cells. Data are
the average of duplicate RNAi samples from a single experiment. Similar
results were obtained from another experiment. (D) PIP5KI  is enriched in
the PM. Endogenous PIP5KI  was detected with anti-PIP5KI pan antibody,
and overexpressed HA-PIP5KI 87 (in cDNA-transfected cells) were stained
with anti-HA. Arrows indicate PM. Bars, 50  m. (E) Differential PIP5KI
membrane association. Fractions obtained after sequential sedimentation
were loaded equivalently, except for the cytosol fraction (CYT), which was
loaded 10 times less. Western blot band intensity was determined by
quantitative densitometry, and expressed as a percent of total recovered,
after correcting for differences in fraction of sample loaded.
Figure 2. PIP5KI pan siRNA blocks histamine-stimulated IP3 generation.
Cells were stimulated with 100  M histamine. (A) Effect of PIP5KI pan
siRNA on IP3 generation. Data shown are representative of five independent
experiments. (B) Effect of PIP5KI RNAi on the initial IP3 peak response.
Values are mean   SEM of multiple independent experiments (n).PHOSPHATIDYLINOSITOL KINASE, CALCIUM • WANG ET AL. 1007
naling. In control cells, 100  M histamine induces a rapid and
transient rise in intracellular Ca
2  concentration ([Ca
2 ]i) in
95% of the cells examined (Fig. 3 A). PIP5KI 87 RNAi re-
duces the percent of responding cells slightly (by 13%), de-
creases the amplitude of the first Ca
2  peak more [by 36%;
from 1.14   0.07 (n   19) to 0.73   0.08 (n   10) fluores-
cence ratio unit], and has the most impact on Ca
2  flux [76%
decrease; from 0.33   0.03 (n   19) to 0.08   0.01 (n   10)
unit/s] (Fig. 3 A). Because Ca
2  flux correlates with the open
probability of the IP3Rs and hence the rate of IP3 generation
(Johenning et al., 2004), our results establish that PIP5KI 87
RNAi depletes the PIP2 pool used for IP3 generation. A simi-
larly large decrease in Ca
2  flux was also observed when PIP2
was depleted by overexpressing the PIP2 phosphatase synapto-
janin (Johenning et al., 2004).
The weakened Ca
2  response by PIP5KI 87 RNAi cells is
not due to depletion of Ca
2  stores, because thapsigargin releases
similar amounts of Ca
2  into the cytosol of control and siRNA
cells (unpublished data). The [Ca
2 ]i response to UTP, which
binds a different GPCR than histamine (P2Y and H1, respec-
tively), is blunted as well (unpublished data). [Ca
2 ]i increase in
the presence of 1.3 mM of extracellular Ca
2  (Table S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200408008/DC1)
is also attenuated, confirming that the lack of PIP2 impacts the
entire Ca
2  signaling cascade that starts with Ca
2  release from
internal stores and ends with capacitative Ca
2  entry (that usu-
ally follows the depletion of intracellular Ca
2  stores).
As expected, in control cells, 1  M histamine induces a
slower Ca
2  flux than 100  M histamine [0.24   0.01 (n   63)
vs. 0.33   0.03 (n   19) fluorescence ratio unit/s]. Paradoxi-
cally, PIP5KI 87 RNAi cells have the same low Ca
2  flux
[0.08   0.01 (n   46) vs. 0.08   0.01 (n   10) fluorescence
ratio unit/s] at both histamine doses. We cannot explain why
this is the case. Perhaps because PIP2 is already limiting at sub-
maximal stimulation, increasing the intensity of the stimulus
does not significantly increase the amount of IP3 generated due
to lack of substrate.
Unlike PIP5KI 87 RNAi, PIP5KI 90,   or   RNAi has
much less effects (Fig. 3 A), paralleling the trend observed
with IP3 production (Fig. 2 B). Thus, the PIP5KI pan siRNA
phenotype can be most simply explained by a decrease in the
amount of PLC  accessible PM PIP2 and that this pool is gen-
erated primarily by PIP5KI 87.
If PIP5KI 87 RNAi suppresses Ca
2  signaling by deplet-
ing PM PIP2, restoring membrane PIP2 should rescue the Ca
2 
response. We used a membrane permeant polyamine shuttle
carrier to deliver exogenous PIP2 into intact cells (Ozaki et al.,
2000; Wang et al., 2003). Control HeLa cells respond to
sequential histamine challenges identically, and Shuttle PIP2
does not change the Ca
2  response significantly (Fig. 3 B).
PIP5KI 87 RNAi cells, which are already less responsive to
the first stimulus than control cells, have an even more blunted
response to the second stimulus in the absence of Shuttle PIP2
(Fig. 3 B, left). This is consistent with depletion of the already
small PIP2 pool by the first stimulus, and inadequate refilling
before the second stimulus. Significantly, Shuttle PIP2 restores
the Ca
2  response of PIP5KI 87 RNAi cells to  74% of that
observed in Ctrl RNAi cells (Fig. 3 B). Therefore, the Ca
2  sig-
naling defect is due to PIP2 depletion by PIP5KI  RNAi.
Together, our results demonstrate that PIP5KI 87 has a
critical role in GPCR-mediated IP3 signaling in HeLa cells. In-
terestingly, overexpressed mouse PIP5KI  (equivalent to hu-
man PIP5KI  described in this paper) stimulates tyrosine ki-
nase receptor activated-IP3 generation in B lymphocytes (Saito
et al., 2003). Together, these results raise the intriguing possi-
bility that the GPCR- and tyrosine kinase receptor-coupled
PIP2 pools may be governed by different PIP5KIs. We plan to
determine if this is the case in future studies.
Effects of PIP5KI 87 RNAi on PIP2 
content and distribution
To understand how PIP5KI 87 uniquely contributes to GPCR
mediated IP3 signaling, we estimated the size and location of its
Figure 3. PIP5KI pan siRNA attenuates intracellular Ca
2  signaling.
Cells loaded with fura2-AM in randomly chosen microscopic fields were
ratio imaged (F340/F380) to obtain baseline Ca
2  values. Histamine was
added in the absence of extracellular Ca
2 , and the ratio image was
recorded as a function of time. (A) Ca
2  response to 100  M histamine
(indicated by the arrow). Representative tracings for each type of RNAi
are shown. Values in bar graphs are expressed as percent (mean   SEM)
of control. (B) In vivo rescue of intracellular Ca
2  signaling in PIP5KI pan
siRNA-treated cells by Shuttle PIP2. Top panels are representative tracings.
(Bottom) The Ca
2  flux of the transients elicited by the second histamine
addition was plotted and 10 cells were analyzed per condition.JCB • VOLUME 167 • NUMBER 6 • 2004 1008
PIP2 pool relative to those of other PIP5KIs. PIP5KI pan siRNA
reduces PIP2 mass, determined by HPLC (Nasuhoglu et al.,
2002), by 14% [from 377   90 (n   3) to 325   95 (n   3)
pmol/mg protein] and 
32P-incorporation into PIP2, determined by
TLC, to a similar extent (Fig. 4 A). PIP5KI 90 siRNA has no
statistically significant effect. PIP5KI  RNAi decreases PIP2
mass by 34% (Fig. 4 A), which is consistent with the large de-
crease in [
32P]PIP2 reported previously (Padron et al., 2003). Par-
adoxically, although PIP5KI  RNAi does not decrease [
32P]PIP2
(Padron et al., 2003), it decreases PIP2 mass by 33%. The differ-
ence between the TLC and HPLC estimates may be because they
measure different parameters. 
32P-labeling/TLC detects PIP2 that
turns over during the labeling period, whereas the HPLC method
does not involve radiolabeling (Nasuhoglu et al., 2002) and mea-
sures PIP2 mass. It is possible that the 4-h labeling interval we
used was not long enough to completely equilibrate a particu-
larly stable PIP2 pool, and therefore underestimates its size.
PIP5KI 87 RNAi decreases PM PIP2 significantly. PIP2
was detected by single cell fluorescence imaging using overex-
pressed GFP-PLC -PH (Varnai and Balla, 1998; Watt et al.,
2002) and anti-PIP2 (Laux et al., 2000; Matsuda et al., 2001;
Fig. 4 B). Although it is generally accepted that the PM is par-
Figure 4. Effect of PIP5KI RNAi on PIP2. (A) PIP2 mass
(HPLC) and 
32P-incorporation (TLC). Means   SEM of
independent experiments are shown. (B) PIP2 distribution
as detected with anti-PIP2 and overexpressed GFP-PLC -
PH. Cross-sectional plots of fluorescence intensity are
shown next to the image. Bars, 50  m. (C) Analysis of
PIP2 quantitation. (Left) The average intensities of anti-PIP2
at the PM and inside the cell are expressed in arbitrary
units (mean   SEM). 10 cells were analyzed per RNAi
condition. (Right) PM/cytoplasmic intensity ratios of anti-PIP2
and GFP-PLC -PH were shown. 10 cells were analyzed
per label per RNAi condition.PHOSPHATIDYLINOSITOL KINASE, CALCIUM • WANG ET AL. 1009
ticularly enriched in PIP2 and that GFP-PLC -PH labels the
PM intensely, internal GFP-PLC -PH labeling has also been
reported in at least some types of cells (Matsuda et al., 2001).
However, because GFP-PLC -PH was overexpressed and also
binds IP3 (Hirose et al., 1999), it is difficult to determine if the
internal GFP-PLC -PH is bound to PIP2/IP3 or represents unli-
ganded PH. This issue is clarified somewhat by a quantitative
immuno-electron microscopic study which shows that the PM
accounts for 40% of total GST-PLC -PH labeling, and internal
organelles account for the remainder (Watt et al., 2002).
Our anti-PIP2 staining results clearly shows that PIP2 is
present in internal membranes as well as PM in HeLa cells. Us-
ing image quantitation (Fig. 4, B and C), we estimate that anti-
PIP2 fluorescence in the vicinity of the PM accounts for 12.3  
1.2% (n   10) of total, and its intensity is 1.54   0.13 times
(n   10) higher than in internal sites (PM/cytosol ratio; Fig. 4
C). Although these cross-sectional analyses underestimate the
size of the PM pool (compared with morphometric analysis by
electron microscopy, as described by Watt et al., 2002), it can
be used to compare the effects of different PIP5KI RNAi.
PIP5KI pan RNAi decreases the PM anti-PIP2 intensity
from 226   7 to 134   8 arbitrary units (59% of control) and
internal PIP2 from 157   12 to 130   12 arbitrary units (84%
of control; Fig. 4 C). Therefore, PM PIP2 is preferentially de-
pleted. PIP5KI  RNAi decreases anti-PIP2 intensity at the PM
to the same extent (to 58% of control; Fig. 4 B) but has a
greater effect on internal PIP2 (71% of control). In contrast,
PIP5KI  RNAi has no detectable effect on PM PIP2 (98% re-
mains after RNAi), but decreases internal staining (76% re-
maining; Fig. 4, B and C). The differential responses of PM
versus internal PIP2 is evident when the average intensity of
PM PIP2 is expressed as a ratio to that in the cytosol (Fig. 4 C,
right). Qualitatively similar, but not identical, changes are also
observed with GFP-PLC -PH (Fig. 4 C). Thus, these two inde-
pendent methods both show that PIP5KI 87 and PIP5KI 
RNAi decrease PM PIP2, even though only the former sup-
presses GPCR-mediated IP3/Ca
2  signaling.
In conclusion, PIP5KI 87 is the major source of the
GPCR mobilized PIP2 pool. This specialized PIP2 accounts for
a small fraction of total PIP2, a significant fraction of PM PIP2
and most of the histamine induced IP3 response. The exquis-
itely selective effect of PIP5KI 87 RNAi on Ca
2  signaling
suggests that the cell’s PIP2 is functionally compartmentalized
in a PIP5KI-dependent manner. This study provides a mecha-
nistic understanding of how PIP2 can regulate multiple PM
functions independently. Additional studies will determine if
PIP5KI 87 is part of the supramolecular PLC  signaling scaf-
fold that specifies rapid local Ca
2  generation and propagation
(Delmas et al., 2004), and whether the functionally compart-
mentalized PIP2 is physically segregated in the PM.
Materials and methods
Antibodies
Anti-PIP5KI  was purchased from Santa Cruz Biotechnology, Inc. Anti-
PIP5KI  and PIP5KI pan were gifts from C. Carpenter (Harvard Medical
School, Boston, MA) and P. De Camilli (Yale University, New Haven, CT;
Wenk et al., 2001), respectively. Monoclonal anti-PIP2 (Fukami et al.,
1988) was a gift from K. Fukami (University of Tokyo, Tokyo, Japan).
RNAi
We used the human PIP5KI isoforms designation, which is different from
the mouse designation. siRNA oligonucleotides were performed as de-
scribed previously (Padron et al., 2003). HeLa cells were transfected with
the siRNA and used 48–72 h later.
Quantitative real-time PCR
RNA extracted from HeLa cells transfected with siRNA were reverse tran-
scribed and used for PCR in a sequence detection system (Prism 7000;
Applied Biosystems). Primers directed at nucleotides 414–478 (pan) and
1993–2048 (unique to PIP5KI 90) were used (Padron et al., 2003).
PIP2 measurements
PIP2 mass was determined by a nonradioactive HPLC detection system
(Nasuhoglu et al., 2002). 
32P-incorporation into PIP2 was determined by
labeling cells for 4 h with 
32P-PO4 (NEN Life Science Products), resolving
lipids by TLC, and quantitation by phosphorimager analysis (Wang et al.,
2003). PM PIP2 was determined by image analysis of cells overexpressing
low amounts of GFP-PLC -PH (Varnai and Balla, 1998), or labeling with
anti-PIP2 (Laux et al., 2000; Matsuda et al., 2001). Fluorescence images
were captured by confocal microscopy (model LSM5; Carl Zeiss MicroIm-
aging, Inc.) and intensity plots were analyzed by MetaMorph Offline soft-
ware (Varnai and Balla, 1998). The average fluorescence intensity of the
two cell edges and between the cell edges were defined as PM and cyto-
plasmic PIP2, respectively, and are expressed in arbitrary units.
Immunofluorescence microscopy
For most purposes, 0.4% formaldehyde fixed cells were permeabilized
with Triton X-100 and processed for confocal microscopy as described
previously (Wang et al., 2003). Anti-PIP2 staining was detected by perme-
abilizing fixed cells with 10  g/ml digitonin, which preserves the lipid
signal better than Triton X-100.
Multistep membrane fractionation
Cells were homogenized by 25 strokes in a prechilled steel homogenizer
and homogenates were centrifuged sequentially to obtain the crude or-
ganelle/membrane fractions as described previously (Wei et al., 2002).
LSP is enriched for Golgi membranes and early endosomes, and HSP is
enriched for lysosomes and late endosomes. The PM fraction was ob-
tained by placing the 19,000 g pellet on top of a sucrose cushion, and
collecting the membranes at the top after centrifugation at 100,000 g.
IP3 measurement
Cell monolayers incubated in Ca
2 -free Hank’s buffer supplemented with
0.1% BSA were stimulated with 100  M histamine (Sigma-Aldrich) for
0–25 s at RT and the reaction was stopped with PCA. IP3 content was as-
sayed by competition with exogenous [
3H]IP3 to bind calf cerebellar mi-
crosomes (Sun et al., 1995).
Single cell Ca
2  imaging
Cells plated on glass-bottom culture dishes (Mat Tek) were loaded with
fura2/AM, washed and incubated for 30 min at RT to allow de-esterifica-
tion of the loaded dye. The dish was mounted on the stage of an inverted
fluorescence microscope (Axiovert 200; Carl Zeiss MicroImaging, Inc.)
with a 40  objective. Cells were excited at 340 and 380 nm and the
change in fluorescence ratio values (F340/F380) as a function of time in indi-
vidual cells within a field was recorded simultaneously. The percent of re-
sponding cells was obtained by dividing those with a Ca
2  signal to total
cells recorded. The ratio of maximal F340/F380 induced by histamine to
basal F340/F380 is defined as the Ca
2  peak. Ca
2  flux is defined as the
slope of a line between the initiation of a persistent increase in F340/F380
and the maximal F340/F380.
Intracellular delivery of PIP2 by Shuttle PIP2
siRNA-treated cells were stimulated with 1  M histamine in the absence of
extracellular Ca
2  and ratio imaged. Histamine was washed out and cells
were loaded with a mixture of 1  M diC16-PIP2 and 1  M of carrier 2
(Shuttle PIP2; Echelon Biosciences, Inc.) diluted in the Hank’s buffer (PIP2) or
buffer only (Mock; Wang et al., 2003) for 10–15 min on the microscope
stage. Cells were then reexposed to 1  M histamine and imaged again.
Online supplemental material
Table S1 illustrates the effect of PIP5KI RNAi on PIP5KI protein expression.
HeLa cells transfected with siRNA for each PIP5KI was lysed and subjected
to Western blotting with isoform specific antibodies. Table S2 illustrates the
effect of PIP5KI RNAi on histamine induced Ca
2+ transients. HeLa cells trans-JCB • VOLUME 167 • NUMBER 6 • 2004 1010
fected with siRNA were stimulated with histamine, and Ca
2+ transients were
recorded on single cells loaded with fura2. Online supplemental material is
available at http://www.jcb.org/cgi/content/full/jcb.200408008/DC1.
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